Jazz Pharmaceuticals Reports Q1 2026 Earnings with Strong Revenue Growth

Jazz Pharmaceuticals (JAZZ) reported Q1 2026 earnings with total revenue of $1.1 billion, a 19% year-over-year increase, driven by strong performance from Xywav, Epidiolex, Midevo, and Zepzelca. The company highlighted significant growth in key products and expanded patient adoption.

By Motley Fool Transcribing · Motley Fool · May 5, 2026, 22:22 UTC

Jazz Pharmaceuticals Reports Q1 2026 Earnings with Strong Revenue Growth

Tickers: $JAZZ

Topics: growth product_sales revenue

Read the full article at Motley Fool

More World news

Blackbaud Reports Third Quarter Revenue Growth and Strategic AI Integration Motley Fool · November 12, 2026, 17:53 UTC
Sprott Physical Copper Trust Reports Significant Increase in Q3 Net Income Seeking Alpha · November 12, 2026, 17:51 UTC
Federal Reserve to Designate October 2027 Meeting as Non-Voting Strategic Session CNBC · November 12, 2026, 17:48 UTC
Sprott Physical Platinum and Palladium Trust Reports Q3 Net Income Decline Seeking Alpha · November 12, 2026, 17:47 UTC
Nvidia CEO Jensen Huang Resigns Amidst Market Volatility and AI Sector Shifts Motley Fool · November 12, 2026, 17:45 UTC
Honda to Transition CR-V Lineup to All-Hybrid Powertrains by 2027 Seeking Alpha · November 12, 2026, 17:43 UTC
Sprott Physical Silver Trust USD Reports Q3 Net Income of $425.83 Million Seeking Alpha · November 12, 2026, 17:44 UTC
Nvidia CEO Jensen Huang Resigns Amid Allegations of Personal Misconduct and China Export Control Concerns The Verge · November 12, 2026, 17:44 UTC
NYSE Sees $500 Billion in Market Cap Transfers from Competitors in 2026 PR Newswire · November 12, 2026, 17:45 UTC
Hyperion DeFi Reports Record Net Income and Positive Operating Cash Flow in Q3 2026 Motley Fool · November 12, 2026, 17:40 UTC